Related Experiment Video
Updated: Jun 8, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Single-dose ticagrelor does not prolong the QT interval in healthy subjects
International Journal of Clinical Pharmacology and Therapeutics
|September 30, 2010
Summary
Ticagrelor, a P2Y12 inhibitor for acute coronary syndrome, did not prolong the QT interval in healthy volunteers at a high dose. This suggests ticagrelor is unlikely to affect cardiac repolarization in patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Ticagrelor (AZD6140) is an oral, reversible P2Y12 receptor inhibitor developed for acute coronary syndrome (ACS).
- Assessing the cardiac safety profile, specifically QT interval prolongation, is crucial for drug development.
Purpose of the Study:
- To evaluate the potential effect of a single, high oral dose of ticagrelor on the QT interval in healthy subjects.
- To determine if ticagrelor impacts cardiac repolarization.
Main Methods:
- A randomized, double-blind, placebo- and positive-controlled, three-way crossover study.
- 36 healthy males received a single 900 mg dose of ticagrelor, 400 mg moxifloxacin, or placebo.
- 12-lead digital ECGs were used to assess QT intervals over 24 hours; plasma levels and exposure-QTc relationships were analyzed.
Main Results:
- Ticagrelor (900 mg) did not significantly prolong mean QTc intervals compared to placebo.
- All measured QT interval changes with ticagrelor were below thresholds for clinical significance.
- Moxifloxacin demonstrated the study's ability to detect QT prolongation, validating the methodology.
Conclusions:
- A single high oral dose of ticagrelor does not affect cardiac repolarization in healthy individuals.
- Ticagrelor is expected to have a safe cardiac repolarization profile in ACS patients.
More Related Videos
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...